Skip to main content
SUNFLOWER PHARMACEUTICAL GROUP CO.,LTD logo

SUNFLOWER PHARMACEUTICAL GROUP CO.,LTD — Investor Relations & Filings

Ticker · 002737 ISIN · CNE100001WT7 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,262 across all filing types
Latest filing 2024-04-25 Audit Report / Informat…
Country CN China
Listing Shenzhen Stock Exchange 002737

About SUNFLOWER PHARMACEUTICAL GROUP CO.,LTD

https://www.kuihuayaoye.com

Sunflower Pharmaceutical Group Co., Ltd. focuses on the research, development, manufacturing, and distribution of proprietary Chinese medicines, chemical drugs, and health supplements. The organization is particularly noted for its specialization in pediatric medicine, marketed under the "Little Sunflower" brand, which includes treatments for respiratory and digestive ailments. Its extensive product portfolio also covers gynecological health and general internal medicine. The group operates several integrated production bases and research institutes, facilitating a comprehensive approach to drug formulation and quality control. By leveraging a robust supply chain and a wide-reaching distribution network, the company provides a diverse range of over-the-counter and prescription solutions aimed at improving family health and wellness.

Recent filings

Filing Released Lang Actions
2023年年度审计报告
Audit Report / Information Classification · 95% confidence The document is titled as an "审计报告及财务报表" (Audit Report and Financial Statements) for the fiscal year 2023, covering the period from January 1, 2023, to December 31, 2023. It includes an audit opinion, basis for the audit, key audit matters, management responsibilities, and detailed consolidated and parent company financial statements such as balance sheets, income statements, and cash flow statements. The document is comprehensive and contains actual financial data and detailed audit commentary, not merely an announcement or certification. Therefore, it fits the definition of an Audit Report / Information (AR) filing, which includes standalone audit reports and applied accounting principles, excluding full annual reports. The document is not a full Annual Report (10-K) as it lacks broader company activity and management discussion sections, nor is it a Regulatory Filing or Report Publication Announcement since it contains substantive financial and audit content. Confidence is high given the detailed audit report and financial statements included. FY 2023
2024-04-25 Chinese
董事会审计委员会对会计师事务所2023年度履职情况评估及履行监督职责情况的报告
Audit Report / Information Classification · 95% confidence The document is a report from the Board Audit Committee evaluating the performance and supervision of the external audit firm for the fiscal year 2023. It discusses the audit firm's qualifications, audit procedures, and the committee's oversight activities related to the audit of the company's 2023 financial statements. The document references the audit report issued by the firm but does not contain the full financial statements or detailed financial data itself. It is a standalone report focused on audit oversight and evaluation, which fits the definition of an Audit Report / Information (AR). The document length is under 5,000 characters but it is not merely an announcement of a report being published; it is the actual committee's report on audit supervision. Therefore, the appropriate classification is AR with high confidence. FY 2023
2024-04-25 Chinese
关于2023年度利润分配方案的公告
Notice of Dividend Amount Classification · 95% confidence The document is an announcement regarding the 2023 annual profit distribution plan of a company, including details on dividends per share, total cash dividends, and compliance with relevant regulations. It includes resolutions from board and supervisory meetings and mentions that the plan will be submitted to the shareholders' meeting for approval. The document is relatively short (1432 characters) and primarily serves to inform shareholders about the dividend distribution proposal rather than presenting full financial statements or detailed financial analysis. It does not contain comprehensive financial data or a full annual report. Therefore, it is best classified as a Notice of Dividend Amount (DIV).
2024-04-25 Chinese
关于使用闲置自有资金进行现金管理的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement from a company regarding the use of idle funds for cash management, detailing investment purpose, amount, risk analysis, control measures, and approval procedures. It is a regulatory announcement about financial management activities, not a full financial report or earnings release. The document is relatively short (1527 characters) and does not contain financial statements or detailed financial data. It is not a report itself but an announcement of a corporate action related to capital management. Therefore, it fits best under Capital/Financing Update (CAP).
2024-04-25 Chinese
独立董事述职报告（林瑞超）
Board/Management Information Classification · 95% confidence The document is titled as an "Independent Director's Work Report" for the year 2023 from a specific independent director of the company. It details the director's attendance at meetings, independent opinions on various company matters, supervision of internal controls, and other governance-related activities. The content focuses on the director's duties, opinions on company governance, internal control reports, and compliance with laws and regulations. It does not contain financial statements or earnings data, nor is it an announcement of voting results or a proxy solicitation. The document is a detailed report on board/management oversight and independent director activities, which fits best under Board/Management Information (MANG). The document length is 3348 characters, which is relatively short but contains substantive content about board activities rather than just an announcement or certification. Therefore, the classification is MANG with high confidence.
2024-04-25 Chinese
2024年一季度报告
Interim / Quarterly Report Classification · 100% confidence The document is titled as a "2024 First Quarter Report" (2024 年第一季度报告) for the company 葵花药业集团股份有限公司. It contains detailed financial data including balance sheets, profit and loss statements, cash flow statements, and explanations of financial metrics for the first quarter of 2024. The document explicitly states it is a quarterly report and is unaudited. The length of the document (over 12,000 characters) and the presence of comprehensive financial statements confirm it is a full interim/quarterly financial report rather than a brief announcement or certification. Therefore, the document fits the definition of an Interim / Quarterly Report (IR). Q1 2024
2024-04-25 Chinese

Browse filings by year

13 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.